Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Beats Expectations By $1.80 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) announced its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80, Zacks reports. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%.

Tonix Pharmaceuticals Stock Performance

TNXP traded down $0.00 during midday trading on Wednesday, hitting $0.14. 10,191,409 shares of the company traded hands, compared to its average volume of 10,131,642. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The company’s 50-day moving average is $0.15 and its 200 day moving average is $1.50. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $22.14.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Alliance Global Partners upped their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.